Pyogenic liver abscesses in liver transplant recipients versus non-transplant population. Outcome and risk factors of patient survival.
abdominal infections
hepatic artery thrombosis
liver abscess
liver transplantation
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
10
02
2023
received:
12
08
2022
accepted:
05
03
2023
medline:
9
6
2023
pubmed:
22
3
2023
entrez:
21
3
2023
Statut:
ppublish
Résumé
Pyogenic liver abscess (PLA) is a life-threatening infection in both liver transplant (LT) and non-LT patients. Several risk factors, such as benign and malignant hepatopancreatobiliary diseases and colorectal tumors have been associated with PLA in the non-LT population, and hepatic artery stricture/thrombosis, biliary stricture, and hepaticojejunostomy in the LT patients. The objective of this study is to compare the outcomes of patients with PLA in LT and non-LT patients and to determine the risk factors associated with patient survival. From January 2000 to November 2020, a total of 296 adult patients were diagnosed of PLA in our institution, of whom 26 patients had previously undergone liver transplantation (LTA group), whereas 263 patients corresponded to the non-LTA population. Seven patients with PLA who had undergone previous kidney transplantation were excluded from this retrospective study. Twenty-six patients out of 1503 LT developed PLA (incidence of 1.7%). Median age was significantly higher in non-LTA patients (p = .001). No significant differences were observed in therapy. PLA recurrence was significantly higher in LTA than in non-LTA (34.6% vs. 14.8%; p = .008). In-hospital mortality was greater in the LT group than in the non-LT group (19.2% vs. 9.1% p = .10) and was identified in multivariable analysis as a risk factor for mortality (p = .027). Mortality rate during follow-up did not show significant differences between the groups: 34.6% in LTA patients versus 26.2% in non-LTA patients (p = .10). The most common causes of mortality during follow-up were malignancies, Covid-19 infection, and neurologic disease. 1-, 3-, and 5-year actuarial patient survival rates were 87.0%, 64.1%, and 50.4%, respectively, in patients of LTA group, and 84.5%, 66.5%, and 51.0%, respectively, in patients with liver abscesses in non-LTA population (p = .53). In conclusion, LT was a risk factor for in hospital mortality, but not during long-term follow-up.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14966Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Yin D, Ji C, Zhang S, et al. Clinical characteristics and management of 1572 patients with pyogenic liver abscess: a 12-year retrospective study. Liver Int. 2021;41:810-818.
Tsai FC, Huang YT, Chang LY, Wang JT. Pyogenic liver abscess as endemic disease. Taiwan Emerg Infect Dis. 2008;14:1592-1600.
Chen YC, Lin CH, Chang SN, Shi ZY. Epidemiology and clinical outcome of pyogenic liver abscess: an analysis from the National Health Insurance Research Database of Taiwan, 2000-2011. J Microbiol Immunol Infect. 2016;49:646-653.
Kaplan GG, Gregson DB, Laupland KB. Population-based study of the epidemiology of and the risk factors for pyogenic liver abscess. Clin Gastroenterol Hepatol. 2004;2:1032-1038.
Meddings L, Myers RP, Hubbard J, et al. A population-based study of pyogenic liver abscesses in the United States: incidence, mortality, and temporal trends. Am J Gastroenterol. 2010;105:117-124.
Alvarez Pérez JA, González JJ, Baldonedo RF, et al. Clinical course, treatment, and multivariate analysis of risk factors for pyogenic liver abscesses. Am J Surg. 2001;181:177-186.
Shi S, Xia W, Guo H, Kong H, Zheng S. Unique characteristics of pyogenic liver abscesses of biliary origin. Surgery. 2016;159:1316-1324.
Yeh TS, Jan YY, Jeng LB, et al. Pyogenic liver abscesses in patients with malignant disease. Arch Surg. 1998;133:242-245.
Njoku VC, Howard TJ, Shen C, et al. Pyogenic liver abscess following pancreaticoduodenectomy: risk factors, treatment, and long-term outcome. J Gastrointest Surg. 2014;18:922-928.
Qu K, Liu C, Wang ZX, et al. Pyogenic liver abscesses associated with nonmetastatic colorectal cancers: an increasing problem in Eastern Asia. World J Gastroenterol. 2012;18:2948-2955.
Mezhir JA, Fong Y, Jacks LM, et al. Current management of pyogenic liver abscess: surgery is now second-line treatment. J Am Coll Surg. 2010;210:975-983.
Shin JU, Kim KM, Shin SW, et al. A prediction model for liver abscess developing after transarterial chemoembolization in patients with hepatocellular carcinoma. Dig Liver Dis. 2014;46:813-817.
Park JG, Park SY, Tak WY, et al. Early complications after percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1,843 ablations in 1,211 patients in a single centre: experience over 10 years. Clin Radiol. 2017;72:692.e9-692e15.
Dabs DN, Stein DM, Scalea TM. Major hepatic necrosis: a common complication after angioembolization for treatment of high-grade liver injuries. J Trauma. 2009;66:621-629.
Tachopoulou OA, Vogt DP, Henderson JM, Baker M, Keys TF. Hepatic abscess after liver transplantation: 1990-2000. Transplantation. 2003;75:79-83.
Foley DP, Fernández LA, Leverson JM. Donation after cardiac death: the University of Wisconsin experience with liver transplantation: 1990-2000. Ann Surg. 2005;242:724-731.
Ikegami T, Hashikura Y, Nakazawa Y, et al. Risk factors contributing to hepatic artery thrombosis following living-donor liver transplantation. J Hepatobiliary Pancreat Surg. 2006;13:1541-1543.
Duffy JP, Hong JC, Farmer DG, et al. Vascular complications of orthotopic liver transplantation: experience in more than 4,200 patients. J Am Coll Surg. 2009;20(208):896-903. discussion 903-905.
Nikeghbalian S, Salahi R, Salahi H, et al. Hepatic abscess after liver transplantation:1997-2008. Exp Clin Transplant. 2009;4:256-260.
Kornasiewicz O, Hotowko W, Grat M, et al. Hepatic abscess: a rare complication after liver transplant. Clin Transplant. 2016;30:1230-1235.
Czerwonko ME, Huespe P, Elizondo CM, et al. Risk factors and outcomes of pyogenic liver abscess in adult liver recipients: a matched case-control study. HPB. 2018;20:583-590.
Fujiki M, Hashimoto K, Palaios E, et al. Probability, management, and long-term outcomes of biliary complications after hepatic artery thrombosis in liver transplant recipients. Surgery. 2017;162:1101-1111.
Lafont E, Roux O, Lastours V, et al. Pyogenic liver abscess in liver transplant recipients: a warning signal for the risk of recurrence and retransplantation. Transpl Infect Dis. 2020;22:e13360.
Justo I, Jiménez-Romero C, Manrique A, et al. Management and outcome of liver abscesses after liver transplantation. World J Surg. 2018;42:3341-3349.
Silva MA, Jambulingam PS, Gunson BK, et al. Hepatic artery thrombosis following orthotopic liver transplantation: a 10-year experience from a single centre in the United Kingdom. Liver Transpl. 2006;12:146-151.
Pomposelli JJ. Hepatic artery thrombosis after liver transplantation: not a surgical problem? Transplantation. 2016;100:2251.
Jiménez-Romero C, Manrique A, Calvo J, et al. Liver transplantation using uncontrolled donors after circulatory death: a 10-year single center experience. Transplantation. 2019;103:2497-2505.
Langnas AN, Marujo WC, Stratta RJ, Wood RP, Shaw BW. Vascular complications after orthotopic liver transplantation. Am J Surg. 1991;161:76-82.
Gunsar F, Rolando N, Pastacaldi S, et al. Late hepatic artery thrombosis after orthotopic liver transplantation. Liver Transpl. 2003;9:605-611.
Said A, Safdar N, Lucey MR, et al. Infected bilomas in liver transplant recipients, incidence, risk factors and implications for prevention. Am J Transplant. 2004;4:574-582.
Jindal A, Pandey A, Sharma MK, et al. Management practices and predictors of outcome of liver abscess in adults: a series of 1630 patients from a liver unit. J Clin Exp Hepatol. 2021;11:312-320.
Kajiya T, Uemura T, Kajiya M, et al. Pyogenic liver abscess related to dental disease in an immunocompetent host. Int Med. 2008;47:675-678.
Lardiere-Deguelte S, Ragot E, Amroun K, et al. Hepatic abscess: diagnosis and management. J Visc Surg. 2015;152:231-243.
Lo JZW, Leow JJJ, Ng PLF, et al. Predictors of therapy failure in a series of 741 adult pyogenic liver abscesses. J Hepatobiliary Pancreat Sci. 2015;22:156-165.
Haidar G, Green M. Intra-abdominal infections in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33:e13595.
Poovorawan K, Pan-ngum W, Soonthornworasiri N, et al. Burden of liver abscess and survival risk score in Thailand: a population-based score. Am J Trop Med Hyg. 2016;95:683-688.
Lee CH, Jo HG, Cho EY, et al. Maximal diameter of liver abscess independently predicts prolonged hospitalization and poor prognosis in patients with pyogenic liver abscess. BMC Infect Dis. 2021;21:171.
Alkofer B, Dufay C, Parienti JJ, Lepennec V, Dargere S, Chiche L. Are pyogenic abscesses still a surgical concern? A Western experience. HPB Surg. 2012;2012:316013.
Jepsen P, Vilstrup H, Schonheyder HC, Sorensen HT. A nationwide study of the incidence and 30-day mortality rate of pyogenic liver abscess in Denmark, 1977-2002. Aliment Pharmacol Ther. 2005;21:1185-1188.
Mischinger HJ, Hauser H, Rabl H, Werkgartner G, Rubin R, Deu E. Pyogenic liver abscess: studies of therapy and analysis of risk factors. World J Surg. 1994;18:852-858.
Lai KC, Cheng KS, Jeng LB, et al. Factors associated with treatment failure of percutaneous catheter drainage for pyogenic liver abscess in patients with hepatobiliary-pancreatic cancer. Am J Surg. 2013;205:52-57.
Shi S, Zhai Z, Zheng S. Pyogenic liver abscess of biliary origin: the existing problems and their strategies. Semin Liv Dis. 2018;38:270-283.
Sharma A, Mukewar S, Mara KC, Dierkhising RA, Kamath PS, Cummins N. Epidemiologic factors, clinical presentation, causes, and outcomes of liver Abscess: a 35-year Olmsted County study. Mayo Clin Proc Inn Qual Out. 2018;2:16-25.